DRNA News and Press, Dicerna Pharmaceuticals Inc.

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...

Dicerna Pharmaceuticals (NASDAQ:DRNA) ticked lower in premarket trading after Novo Nordisk (NYSE:NVO) disclosed that its withdrew its HSR filing yesterday with the intention of refiling it tomorrow. Novo withdrew its Nov. 22 filing with U.S. antitrust regulators, according to a filing.&#...

Shares of Roivant Sciences (ROIV +33.8%) are surging thanks to Arbutus Biopharma's (ABUS +68.0%) patent dispute win over Moderna (MRNA -7.7%). As of last month, Roivant owns 29.1% of Arbutus common shares. Roivant made a $116M strategic investment in Arbutus in October 2017. Seeking Alpha con...

Danish pharmaceutical giant, Novo Nordisk (NYSE: NVO) made a lot of headlines recently with a big buyout offer for Dicerna Pharmaceuticals (NASDAQ: DRNA) . Novo Nordisk offered Dicerna shareholders a great big 80% premium , leading investors to wonder which biotech stock...

NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: CoreSite Realty Corporation (NYSE:COR) concerning potential violations of the federal securities laws and/or breaches of fiduciary ...

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New ...